Emerging Roles of Myeloid-Derived Suppressor Cells in Diabetes

Shiqi Wang; Qian Tan; Yayi Hou; Huan Dou

doi:10.3389/fphar.2021.798320

Emerging Roles of Myeloid-Derived Suppressor Cells in Diabetes

Front Pharmacol. 2021 Dec 16:12:798320. doi: 10.3389/fphar.2021.798320. eCollection 2021.

Authors

Shiqi Wang^{1

2

3}, Qian Tan³, Yayi Hou^{1

2}, Huan Dou^{1

2}

Affiliations

¹ The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing, China.
² Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, Nanjing, China.
³ Department of Burns and Plastic Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.

Abstract

Diabetes is a syndrome characterized by hyperglycemia with or without insulin resistance. Its etiology is attributed to the combined action of genes, environment and immune cells. Myeloid-derived suppressor cell (MDSC) is a heterogeneous population of immature cells with immunosuppressive ability. In recent years, different studies have debated the quantity, activity changes and roles of MDSC in the diabetic microenvironment. However, the emerging roles of MDSC have not been fully documented with regard to their interactions with diabetes. Here, the manifestations of MDSC and their subsets are reviewed with regard to the incidence of diabetes and diabetic complications. The possible drugs targeting MDSC are discussed with regard to their potential of treating diabetes. We believe that understanding MDSC will offer opportunities to explain pathological characteristics of different diabetes. MDSC also will be used for personalized immunotherapy of diabetes.

Keywords: MDSC; diabetes; diabetic complications; diabetic refractory wounds; recruitment; targeted therapy.

Publication types

Review